drugset
drugset / Trial / NCT02254538

A Safety, Tolerability and Preliminary Pharmacokinetics of BILR 355 BS Single-rising Dose Study in Healthy Male Volunteers

NCT02254538 ↗

Phase 1 Completed 54 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Assessment of safety, tolerability and preliminary pharmacokinetics in healthy male volunteers after oral administration of BILR 355 BS

Timeline

Start
2002-05
Primary completion
2003-02
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BILR 355 BS Unknown — Oral

Indications

No indication recorded.